About us
(Seoul=Yonhap Infomax) Pil Joong Jeong = Samsung Bioepis Co., a leading South Korean biopharmaceutical company specializing in biosimilars, announced on the 25th that it has promoted a total of six executives, including two Executive Vice Presidents and four Senior Vice Presidents, based on its performance-driven principles.
The company stated that Shin Dong-hoon, Executive Vice President and Head of Development Division 2, is a clinical medicine expert with a background as a physician. Leveraging his experience in biosimilar clinical design, medical review, and advisory roles, Shin has established clinical and regulatory strategies for new drug development.
Shin Ji-eun, Executive Vice President and Head of the MSAT (Manufacturing Science & Technology) Team in Development Division 1, is recognized as a development specialist with expertise in process development and technology transfer. She has been credited for optimizing manufacturing processes and identifying new business partners.
An So-shin, Senior Vice President and Head of the Clinical Development Group within the Product Evaluation (PE) Team, has been acknowledged for establishing non-clinical new drug development processes and leading clinical design for new drug development.
Jung Ui-han, Senior Vice President and Head of the RA3 Group within the Regulatory Affairs (RA) Team, expanded the number of countries where the company has obtained marketing approvals. Meanwhile, Lee Nam-hoon, Senior Vice President and Head of the Business Strategy Group within the Strategy Team, played a key role in transitioning to a holding company structure and formulating strategies for new business initiatives.
Son Sung-hoon, Senior Vice President and Head of the Legal Group, is an overseas attorney with expertise in intellectual property (IP), supporting patent applications and related matters.
joongjp@yna.co.kr
(End)
Copyright © Yonhap Infomax Unauthorized reproduction and redistribution prohibited.